N-3 fatty acid &binding protein MRG on mammary tumor

Information

  • Research Project
  • 6541042
  • ApplicationId
    6541042
  • Core Project Number
    R01CA093542
  • Full Project Number
    1R01CA093542-01A1
  • Serial Number
    93542
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/2002 - 23 years ago
  • Project End Date
    7/31/2003 - 22 years ago
  • Program Officer Name
    JHAPPAN, CHAMELLI
  • Budget Start Date
    8/1/2002 - 23 years ago
  • Budget End Date
    7/31/2003 - 22 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    7/15/2002 - 23 years ago

N-3 fatty acid &binding protein MRG on mammary tumor

DESCRIPTION (provided by applicant): There is an increasing public interest in chemoprevention by natural agents such as n-3 polyunsaturated fatty acids (PUFAs) DHA and EPA and the pregnancy-induced differentiation against breast cancer incidence. The mechanisms underlying these preventive effects are currently unknown. Little is known about the regional and developmental expression of locally acting factors in the mammary epithelium that interact with n-3 PUFA and exert differentiating effect during pregnancy. Within this content, a novel mammary derived growth inhibitor and a fatty acid binding protein (FABP) has recently been identified, characterized, and named Mammary derived growth inhibitor Related Gene (MRG). As a new member in the family of FABP, MRG has the highest binding affinity to n-3 PUFA DHA. The preliminary data indicate: (1) MRG overexpression suppresses breast cancer cell growth in vitro and tumorigenesis in vivo. (2) MRG induces differentiation of mammary epithelium and its expression is associated with human mammary gland differentiation. (3) MRG synergistically interacts with DHA in growth inhibition. The present application is to test the hypotheses that (a) MRG is a mediator for intracellular accumulation of n-3 PUFAs in mammary epithelial cells and mediates tumor suppressing effect of n-3 PUFAs on mammary tumors. In this regard, one of mechanisms for pregnancy-induced prevention may be mediated in part by PUFA composition change in mammary gland which favors the ratio of n-3 PUFAs to n-6 PUFAs following pregnancy and lactation; (b) MRG is mediator of the differentiating effects of pregnancy on breast epithelium and overexpression of MRG in young nulliparous mice can induce differentiation and protect the development of mammary tumors. We propose a series of studies of both in vitro and in MMTV/MRG transgenic mice to evaluate the role of MRG on mammary differentiation and tumorigenesis and its interaction with n-3 PUFA on mammary tumorigenesis. These studies will help to identify MRG as mediator for differentiation for mammary gland and for interaction with n-3 PUPA on inhibition of mammary tumorigenesis.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R01
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    259369
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    396
  • Ed Inst. Type
  • Funding ICs
    NCI:259369\
  • Funding Mechanism
  • Study Section
    MEP
  • Study Section Name
    Metabolic Pathology Study Section
  • Organization Name
    LONG ISLAND JEWISH MEDICAL CENTER
  • Organization Department
  • Organization DUNS
  • Organization City
    NEW HYDE PARK
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    11040
  • Organization District
    UNITED STATES